Health
ESMO Guidelines Discourage Delayed, Discontinued Treatment During the COVID-19 Pandemic – OncLive
Any type of anti-cancer therapy that could impact overall survival should not be discontinued or delayed.
Any type of anti-cancer therapy that could impact overall survival (OS) should not be discontinued or delayed, according to a European Society for Medical Oncology (ESMO) interdisciplinary expert consensus paper on how to manage patients with cancer during the coronavirus disease 2019 (COVID-19) pandemic.1
The guidelines, which were recently published in the Annals of Oncology,2 also discourage classifying all patients with cancer as especially vulnerable to COVID-19, regardless of age, gender,…
-
Noosa News18 hours agoMan dies in Brisbane crash, women and girl rushed to hospital
-
Noosa News24 hours agoChilling new details emerge in terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
Business23 hours agoAre BHP shares are buy after its results?
-
Business13 hours agoprofit up 7%, guidance strong